At the 2020 annual conference of the Washington, D.C.-based Food and Drug Law Institute (FDLI), held virtually on October 6-8, Center for Biologics Evaluation and Research (CBER) Director Peter Marks provided valuable insights on the difficult terrain that the regulators at CBER have to navigate to reach their goal of making effective vaccines and therapeutics for COVID-19 available as efficiently as possible.
IPQ’s virtual meeting schedule through October includes:
DIA Annual Canadian Meeting (Oct 19-20)
Xavier Combination Products Summit (Oct 20-30)
AAPS 2020 PharmSci 360 (Oct 26-Nov 5)
DIA China Annual Meeting (Oct 27-30)